

Table 1. Summary of lipid data for LANTUS (from 4002 Study) and AMARYL (from two AMARYL studies with placebo control)

Variable	Subgroup by TG baseline range	Sample size	Treatment	Baseline	Endpoint	Change at Endpoint (Mean/SD)	% reduction from baseline	LANTUS - AMARYL
Triglycerides	300-500	44	LANTUS	362	240	-122.5/102	34%	15%
	500-1000	50	AMARYL	390	321	-70.0/11	18%	52.5
	300-1000	23	LANTUS	391	409	-252.0/208	38%	5%
300-1000	16	AMARYL	662	445	-217.6/88	33%	34.4	
	69	LANTUS	470	301	-169.4/60	36%	13%	63.6
	66	AMARYL	459	350	-105.8/47	23%	21.7	
200-500	124	LANTUS	288	232	-56.3/17	25%	12%	
	129	AMARYL	299	265	-34.6/107	12%	21.9	
	44	LANTUS	180	152	-27.6/36	15%	12%	
Non-HDL Cholesterol	300-500	50	AMARYL	203	178	-5.7/32	3%	
	500-1000	25	LANTUS	186	171	-14.1/35	8%	-2%
	16	AMARYL	224	200	-23.1/35	10%	-9.0	
300-1000	69	LANTUS	181	163	-18.5/40	10%	8.5	
	66	AMARYL	209	198	-9.9/33	5%	5%	
	200-500	124	LANTUS	167	155	-12.5/33	7%	5.8
HDL	129	AMARYL	197	191	-6.7/30	3%		
	44	LANTUS	40	40	0.0/16			
	30	AMARYL	36	37	1.2/6			
500-1000	25	LANTUS	33	36	3.1/7			
	16	AMARYL	37	39	1.6/6			
	69	LANTUS	37	38	1.2/7			
200-500	66	AMARYL	36	37	1.3/6			
	124	LANTUS	42	41	-0.6/8			
	129	AMARYL	38	39	1.2/5			
LDL	All	306	LANTUS	113	110	-3.3/27		
		272	AMARYL	142	140	-1.5/23		